This company has been acquired
AGTC Stock Overview
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Applied Genetic Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$2.83 |
| 52 Week Low | US$0.23 |
| Beta | 1.58 |
| 1 Month Change | -4.23% |
| 3 Month Change | -1.85% |
| 1 Year Change | -80.89% |
| 3 Year Change | -86.79% |
| 5 Year Change | -89.78% |
| Change since IPO | -97.33% |
Recent News & Updates
Recent updates
AGTC receives positive feedback from FDA for manufacturing facility
Jul 26Applied Genetic Technologies proposes stock offering to fund clinical trials
Jul 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022
Jan 12An Assessment Of Applied Genetic Technologies Corporation
Dec 14Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Jul 15Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21
Applied Genetic trades lower after announcing the departure of chief scientific officer
Apr 26What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Feb 05
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 11Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic
Nov 11Shareholder Returns
| AGTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.8% | -2.5% | -3.2% |
| 1Y | -80.9% | -3.7% | 19.3% |
Return vs Industry: AGTC underperformed the US Biotechs industry which returned -10.2% over the past year.
Return vs Market: AGTC underperformed the US Market which returned -14.8% over the past year.
Price Volatility
| AGTC volatility | |
|---|---|
| AGTC Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AGTC's share price has been volatile over the past 3 months.
Volatility Over Time: AGTC's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 102 | Sue Washer | agtc.com |
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease.
Applied Genetic Technologies Corporation Fundamentals Summary
| AGTC fundamental statistics | |
|---|---|
| Market cap | US$12.62m |
| Earnings (TTM) | -US$70.23m |
| Revenue (TTM) | US$325.00k |
38.9x
P/S Ratio-0.2x
P/E RatioIs AGTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGTC income statement (TTM) | |
|---|---|
| Revenue | US$325.00k |
| Cost of Revenue | US$21.76m |
| Gross Profit | -US$21.44m |
| Other Expenses | US$48.80m |
| Earnings | -US$70.23m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | -6,596.62% |
| Net Profit Margin | -21,610.46% |
| Debt/Equity Ratio | 92.6% |
How did AGTC perform over the long term?
See historical performance and comparison